<?xml version="1.0" encoding="UTF-8"?>
<p id="Par39">Given the evidence that an exuberant inflammatory response contributes to the pathogenesis of severe influenza with pneumonitis and/or acute respiratory distress syndrome,
 <sup>
  <xref ref-type="bibr" rid="CR5">5</xref>,
  <xref ref-type="bibr" rid="CR81">81</xref>
 </sup> it seems appropriate to consider using immunomodulatory agents
 <sup>
  <xref ref-type="bibr" rid="CR82">82</xref>
 </sup> in addition to targeting viral replication. Such interventions have shown potential benefits 
 <italic>in vitro</italic>, in observational studies or in animal models.
 <sup>
  <xref ref-type="bibr" rid="CR83">83</xref>,
  <xref ref-type="bibr" rid="CR84">84</xref>
 </sup> Proposed approaches include the use of macrolides
 <sup>
  <xref ref-type="bibr" rid="CR85">85</xref>,
  <xref ref-type="bibr" rid="CR86">86</xref>
 </sup> and statins
 <sup>
  <xref ref-type="bibr" rid="CR87">87</xref>
 </sup> but the clinical benefits of immunomodulation have been hard to demonstrate.
 <sup>
  <xref ref-type="bibr" rid="CR88">88</xref>
 </sup> Corticosteroid treatment of hospitalised patients with influenza is generally to be avoided.
 <sup>
  <xref ref-type="bibr" rid="CR89">89</xref>,
  <xref ref-type="bibr" rid="CR90">90</xref>
 </sup>
</p>
